Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
暂无分享,去创建一个
K. Khunti | M. Jørgensen | K. Birkeland | A. Fu | N. Hammar | E. Wittbrodt | J. Bodegård | M. Kosiborod | John P H Wilding | R. Holl | P. Fenici | M. Thuresson | M. Cavender | A. Norhammar
[1] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[2] B. Carstensen,et al. Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study , 2017, Diabetes, obesity & metabolism.
[3] B. Zinman,et al. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial , 2017, Diabetes Care.
[4] B. Carstensen,et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. , 2017, The Lancet Diabetes and Endocrinology.
[5] K. Khunti,et al. Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study , 2017 .
[6] K. Khunti,et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs , 2017, Circulation.
[7] Darren K Mcguire,et al. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. , 2016, European heart journal.
[8] D. Fitchett,et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.
[9] E. Ferrannini,et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis , 2016, Diabetes Care.
[10] J. McMurray,et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? , 2016, Diabetologia.
[11] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[12] B. Zinman,et al. SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials , 2015, Diabetes & vascular disease research.
[13] T. Münzel,et al. The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity , 2014, PloS one.